Abstracts Archive - Page 2476 of 2607 - ACR Meeting Abstracts

Abstract Number: 1937 • 2012 ACR/ARHP Annual Meeting
HLA-DRB1*0101/*0405 Is Associated with Susceptibility to Anti-MDA5 Antibody-Positive Dermatomyositis in the Japanese Population
Takahisa Gono¹, Yasushi Kawaguchi¹, Masataka Kuwana², Tomoko Sugiura¹, Takefumi Furuya¹, Kae Takagi¹, Hisae Ichida¹, Yasuhiro Katsumata¹, Masanori Hanaoka¹, Yuko Okamoto¹, Yuko Ota¹, Sayuri Kataoka¹ and Hisashi Yamanaka¹, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: The complication of interstitial lung disease (ILD) is associated with the anti-aminoacyl tRNA synthetase antibody (ARS ab) or the anti-melanoma differentiation-associated gene 5 antibody…
Abstract Number: 1938 • 2012 ACR/ARHP Annual Meeting
A New Enzyme-Linked Immunosorbent Assay System for Detecting Autoantibodies to Aminoacyl-tRNA Synthetases: Clinical Usefulness in Myositis and Interstitial Pneumonia
Ran Nakashima¹, Yoshitaka Imura², Minae Seto³, Akihiro Murakami³, Yuji Hosono⁴, Kizuku Watanabe⁵, Tomohiro Handa⁵, Michiaki Mishima⁵, Michito Hirakata⁶, Tsutomu Takeuchi⁷, Keishi Fujio⁸, Kazuhiko Yamamoto⁹, Hitoshi Kohsaka¹⁰, Yoshinari Takasaki¹¹, Noriyuki Enomoto¹², Kingo Chida¹², Toshihiro Nukiwa¹³ and Tsuneyo Mimori¹, ¹Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ³Medical & Biological Laboratories Co., Ltd., Ina, Japan, ⁴Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁵Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan, Kyoto, Japan, ⁶Internal Medicine, Keio University, Tokyo, Japan, ⁷Keio University School of Medicine, Tokyo, Japan, ⁸Department of Allergy and Rheumatology, The University of Tokyo, Tokyo, Japan, ⁹Department of Allergy & Rheumatology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan, ¹⁰Department of Medicine and Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan, ¹¹Division of Rheumatology, Department of Internal Medicine, Juntendo University, Tokyo, Japan, ¹²Hamamatsu University School of Medicine, Hamamatsu, Japan, ¹³Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan

Background/Purpose: Autoantibodies to aminoacyl-tRNA synthetases (ARS) are the most frequent myositis-specific antibodies and they are useful in the diagnosis and management of polymyositis (PM)/ dermatomyositis…
Abstract Number: 1899 • 2012 ACR/ARHP Annual Meeting
Factors Contributing to Non-Publication of Abstracts Presented At the American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting
Jennifer M.P. Woo¹, Daniel Furst², Deborah K. McCurdy³, Olivia I. Lund⁴, Rotem Eyal⁴, Cijin Piao⁴ and Gil Amarilyo¹, ¹Pediatrics/Rheumatology, Mattel Children's Hospital, University of California, Los Angeles, Los Angeles, CA, ²David Geffen School of Medicine, Div of Rheumatology, University of California at Los Angeles, Los Angeles, CA, ³Pediatric Rheumatology, UCLA Division of Pediatric Rheumatology, Los Angeles, CA, ⁴David Geffen School of Medicine at UCLA, Los Angeles, CA
Background/Purpose: The American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Scientific Meeting (ASM) provides a premier forum for the rapid dissemination of novel…
Abstract Number: 1900 • 2012 ACR/ARHP Annual Meeting
Mormed Project: A New 21^st Century Web Platform for Multilingual Communication in systemic Lupus Erythematosus and Antiphospholipid Syndrome
Oier Ateka-Barrutia¹, Adriane Rinsche², Maria Laura Bertolaccini¹, Munther A. Khamashta¹ and MORMED consortium³, ¹Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, ²Language Technology Center Ltd., Kingston, United Kingdom, ³EU
Background/Purpose: The internet is used nowadays as the preferred repository where people search for, access and publish information on any topic. However, language barriers prevent…
Abstract Number: 1901 • 2012 ACR/ARHP Annual Meeting
Chronic Gout. Improvement According to Outcome Meaures in Rheumatology Domains in Daily Clinical Practice
Janitzia Vazquez-Mellado¹, Betsabé Serrano¹, Jaime Mendoza², Sergio Garcia-Mendez¹, V.Chantal Hernández¹, Virginia Pascual Ramos³, Ruben Burgos-Vargas¹ and Marina Rull-Gabayet², ¹Rheumatology, Hospital General de Mexico, Mexico city, Mexico, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³Dept de Immunología y Reumato, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: OMERACT has proposed domains to evaluate the effect of treatment in patients with acute and chronic gout. Their frequency, time to improve and percentage…
Abstract Number: 1902 • 2012 ACR/ARHP Annual Meeting
What Factors Are Associated with Target Serum Urate Concentrations in Patients with Gout?
Nicola Dalbeth¹, Meaghan House², Anne Horne², Keith J. Petrie³, Fiona M. McQueen⁴ and William Taylor⁵, ¹Medicine, University of Auckland, Auckland, New Zealand, ²Department of Medicine, University of Auckland, Auckland, New Zealand, ³University of Auckland, Auckland, New Zealand, ⁴Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand, ⁵University of Otago, Wellington, New Zealand
Background/Purpose: Long term serum urate (SU) lowering to a target of
Abstract Number: 1903 • 2012 ACR/ARHP Annual Meeting
Oxidation of Urate to Allantoin by Myeloperoxidase in Gout
Lisa K. Stamp¹, Irada Khalilova², Mei Zhang¹, Rufus Turner² and Anthony Kettle², ¹Department of Medicine, University of Otago, Christchurch, Christchurch, New Zealand, ²Pathology, University of Otago, Christchurch, Christchurch, New Zealand
Background/Purpose : Hyperuricaemia is critical for the development of gout and may play a pivotal role in the pathophysiology of hypertension, metabolic syndrome, and cardiovascular…
Abstract Number: 1904 • 2012 ACR/ARHP Annual Meeting
Patterns of Gout Treatment and Related Outcomes in US Community Rheumatology Practices: the Relation Between Gout Flares, Time in Treatment, Serum Uric Acid Level and Urate Lowering Therapy
Max I. Hamburger¹, John RP Tesser², John L. Skosey³, Allan H. Morton⁴ and Karl M. Kilgore⁵, ¹Rheumatology Associates, Melville, NY, ²AZ Arthritis Rheum Assoc, Paradise Valley, AZ, ³Illinois Bone & Joint Institut, Chicago, IL, ⁴Warren, MI, ⁵Cetus Group, LLC, Hunt Valley, MD
Background/Purpose: Study patterns of gout treatment and related outcomes in US community rheumatology practices, specifically the relation between likelihood and severity of gout flares, time…
Abstract Number: 1905 • 2012 ACR/ARHP Annual Meeting
Increase of Thyroid Stimulating Hormone in Patients On Febuxostat Treatment
Fernando Perez-Ruiz¹ and Ana M. Herrero-Beites², ¹Servicio de Reumatologia, Hospital Universitario Cruces, Baracaldo, Spain, ²Physical Medicine Division, Hospital de Gorliz, Gorliz, Spain
Background/Purpose: to evaluate whether TSH increases during febuxostat treatment and factors that could be implicated.Methods: before starting febuxostat, patients had analysis at baseline and month…
Abstract Number: 1906 • 2012 ACR/ARHP Annual Meeting
Changes in Gout patient´s Clinical Profile in the Last Two Decades
Fernando Perez-Ruiz¹ and Ana M. Herrero-Beites², ¹Servicio de Reumatologia, Hospital Universitario Cruces, Baracaldo, Spain, ²Physical Medicine Division, Hospital de Gorliz, Gorliz, Spain
Background/Purpose: to assess whether changes in the clinical profile of gout are observed in a large cohort of gout patients over the last 20 years.…
Abstract Number: 1907 • 2012 ACR/ARHP Annual Meeting
Pharmacological Management of Gout in Italy in the Years 2005-2009: A Nationwide, Population-Based Study
Lorenzo Cavagna¹, Gianluca Trifirò², Roberto Caporali³, P. Morabito², C. Ferrajolo⁴, S. Pecchioli⁵, M. Simonetti⁵, G. Medea⁶, C. Cricelli⁷, A. Caputi², G. Mazzaglia⁵ and Carlomaurizio Montecucco⁸, ¹Rheumatology, University and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ²Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Italy, ³Division of Rheumatology, IRCCSPoliclinico S. Matteo Foundation, Pavia, Italy, ⁴Department of Experimental Medicine, Pharmacology Section, Second University of Naples, Naples, Italy, ⁵Health Search, Italian College of General Practitioners, Italy, ⁶Italian college of General Practitioner, Italy, ⁷Italian college of General Practitioner, Pavia (italy), Italy, ⁸Division of Rheumatology, University of Pavia School of Medicine, IRCCS Policlinico San Matteo Foundation, Pavia, Italy
Background/Purpose: Despite the increasing interest on gout, only few nationwide drug utilization studies have been conducted on this topic. The aim of this study…
Abstract Number: 1908 • 2012 ACR/ARHP Annual Meeting
Multinational Evidence-Based Recommendations for Diagnosis and Management of Gout: Integrating Systematic Literature Research and Expert Opinion of a Broad Panel of Rheumatologists in the 3E Initiative
Mariano Andres¹, Francisca Sivera², Alison Kydd³, John Moi⁴, Rakhi Seth⁵, Melonie K. Sriranganathan⁶, Caroline van Durme⁷, Irene AAM van Echteld⁸, Ophir Vinik⁹, Mihir D. Wechalekar¹⁰, Daniel Aletaha¹¹, Claire Bombardier⁹, Rachelle Buchbinder¹², Loreto Carmona¹³, Christopher J. Edwards¹⁴, R. Landewe¹⁵ and Désirée van der Heijde¹⁶, ¹Seccion Reumatologia, Hospital General Universitario de Alicante, Alicante, Spain, ²Sección de Reumatología, Hospital General Universitario de Elda, Alicante, Spain, ³Division of Rheumatology, University of British Columbia, Vancouver, BC, Canada, ⁴Royal Melbourne Hospital, Melbourne, Australia, ⁵Rheumatology, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, ⁶Rheumatology, St. Mary's Hospital, Isle of Wight, United Kingdom, ⁷Maastricht University Medical Centre, Maastricht, Netherlands, ⁸Atrium Medical Center, Heerlen, Netherlands, ⁹Rheumatology, University of Toronto, Toronto, ON, Canada, ¹⁰Flinders University School of Medicine, Adelaide, Australia, ¹¹Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ¹²Monash Department of Clinical Epidemiology at Cabrini Hospital, Department of Epidemiology and Preventive Medicine, Monash University, Malvern, Victoria, Australia, ¹³Health Sciences School, Universidad Camilo José Cela, Villanueva de la Cañada, Spain, ¹⁴NIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, ¹⁵Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ¹⁶Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The 3e (Evidence, Expertise, Exchange) Initiative is a multinational collaboration that aims to promote evidence-based medicine in rheumatology. The 2011-12 3e Initiative aimed to…
Abstract Number: 1909 • 2012 ACR/ARHP Annual Meeting
Use of Uric Lowering Therapies within a Large Health Care System
Robert A. Overman¹, Brian F. Mandell² and Chad L. Deal³, ¹Rheumatology, Cleveland Clinic Foundation, Cleveland, OH, ²Dept of Rheum/Immun NA10, The Cleveland Clinic, Cleveland, OH, ³Dept of Rheum & Imm Dis /A 50, Cleveland Clinic, Cleveland, OH
Background/Purpose: Guidelines for initiating urate lowering therapy (ULT) in the treatment of gout recommend treatment to a target serum urate (SUA) level of ≤6mg/dl with…
Abstract Number: 1910 • 2012 ACR/ARHP Annual Meeting
Regulation of Microrna 223 Expression in a Gouty Arthritis
Gianina Statache¹, Ashleigh-Ann Rainey¹, Seth Masters², Andra Balanescu³, Iain B. McInnes⁴ and Mariola Kurowska-Stolarska⁵, ¹Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Immunology Research Centre, Trinity College Dublin, Dublin, United Kingdom, ³Internal Medicine and Rheumatology, University of Medicine and Pharmacy, Bucharest, Romania, ⁴University of Glasgow, Glasgow, United Kingdom, ⁵Institute of Infection,Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Gout is an inflammatory chronic disease caused by deposition of uric acid crystals in the joint and connective tissues causing pain and disability. Current…
Abstract Number: 1911 • 2012 ACR/ARHP Annual Meeting
Efficacy and Safety of Canakinumab Vs Triamcinolone Acetonide in Patients with Gouty Arthritis Unable to Use Nonsteroidal Anti-Inflammatory Drugs and Colchicine, and On Stable Urate Lowering Therapy (ULT) or Unable to Use ULT
T. Bardin¹, A. So², R. Alten³, M. Bloch⁴, M. R. John⁵, G. Krammer⁵, J. M. Nebesky⁵, A. Tao⁶ and N. Schlesinger⁷, ¹Service de Rhumatologie, Hôpital Lariboisière, Paris, France, ²Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland, ³Charité Univ Medicine, Berlin, Germany, ⁴Holdsworth House Medical Practice, Sydney, Australia, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁷UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ
Background/Purpose: The primary treatment goals for gouty arthritis (GA) are rapid relief of pain and inflammation during acute attacks, and long-term hyperuricemia management. A post-hoc…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].